Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review

Neurology Asia

Volumn 13, Issue , 2008, Pages 15-21

  Lim, Kheng Seang ^a,c   Kwan, Patrick ^b   Tan, Cong Tin ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450; GLUTATHIONE TRANSFERASE; HLA B ANTIGEN; LAMOTRIGINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PHENOBARBITAL; PHENYTOIN;

ASIAN; CHINESE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; INCIDENCE; INDIA; JAPAN; KOREA; MORBIDITY; MORTALITY; PATHOGENESIS; PHARMACOGENETICS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PREVALENCE; REVIEW; SKIN MANIFESTATION; SRI LANKA; STEVENS JOHNSON SYNDROME; THAILAND; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; ALLELE; BULLOUS DERMATITIS; CLINICAL RESEARCH; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG ERUPTION; MACULOPAPULAR RASH; MALAYSIA; POPULATION RISK; RESPIRATORY DISTRESS; SEPSIS; SKIN DISEASE; SURVIVOR;

EID: 67650349868     PISSN: 18236138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004;428.
2. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics 2006; 16:297-306.
3. Lonjou C, Thomas L, Borot, N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6(4):265-8.
4. FDAAlert. Information for Healthcare Professionals Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). Available in URL: http://www.fda.gov:80/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm
5. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
6. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxicepidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102(6):28S-30S
7. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-7.
8. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126:37-42.
9. Revuz JR, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients. Arch Dermatol 1987; 123:1160-4.
10. Faich GA, Knapp D, Dreis M, and Turner W. National adverse drug reaction surveillance. J Am Med Assoc 1987; 257:2068-70.
11. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48:839-46.
12. Stewart RB, May FE, Cullen SI. Dermatologic adverse drug reactions in hospitalized patients. Am J Hosp Pharm 1979; 36:609-12.
13. Bigby M, Jick S, lick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358-63.
14. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765-70.
15. Rademaker M, Oakley A, Duffill MB. Cutaneous adverse drug reactions in a hospital setting. NZ Med J 1995; 108:165-6.
16. Khoo AKM, Foo CL. Toxic epidermal necrolysis in a bums centre: A 6-year review. Burns 1996; 22:275-8.
17. Kamaliah MD, Zainal D, Mokhtar N, Nazmi N. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol 1998; 37:520-3.
18. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxicepidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126(l):43-7.
19. Strom BL, Carson JL, Halpern AC, et al. Apopulation-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991; 127(6):831-8.
20. Messenheimer J. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis among new users of antiepileptic drugs. Neurology 2004; 62(7)(Suppl5):A352
21. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190-4.
22. Wolkenstein P, Revuz J. Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf 1995; 13(l):56-68.
23. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidermiologic study from West Germany. Arch Dermatol 1991; 127(6):839-42.
24. Ronald Farkas, Clinical Review, Adverse Events of Carbamazepine. Available in URL: http://www.fda.gov/cder/foi/nda/2007/ 016608s098,020712s029,021710_ClinRev.pdf
25. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64(7):1134-8.
26. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49(2):542-6.
27. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155:2285-90.
28. Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. Personalized Med 2005; 2:225-37.
29. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40:985-91.
30. Faich GA, Knapp D, Dreis M, Turner W. National adverse drug reaction surveillance. J Am Med Assoc 1997; 257:2068-70.
31. Cao K, Hollenbach JA, Shi XJ, Shi WX, Chopek M, Fernández-Vina MA. HLA-A, -B and -Cw allele frequencies in an Asian population from the USA. Human Immunology 2004; 65(9-10):1194-6.
32. Cao K, Hollenbach JA, Shi XJ, Shi WX, Chopek M, Fernández-Vina MA. HLA-A, -B and -Cw allele frequencies in a Native Amerindian population from the USA. Humart Immunology 2004; 65(9-10):1208-11.
33. Cao K, Hollenbach JA, Shi XJ, Shi WX, Chopek M, Fernández-Vina MA. HLA-A, -B and -Cw allele frequencies in an Asian population from the USA. Human Immunology 2004; 65(9-10):1194-6.
34. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7(6): 813-8.
35. Marcos CY, Theiler GC, Capucchio M, Fainboim L. HLA-A, -B, -DPB1, -DQA1, -DQB1 and -DRB1 allele frequencies in a Wichis Amerindian population from Argentina. Human Immunology 2004; 65(9-10): 860-1.
36. Man CBL, Kwan P, Baum L, et al. Association between HLA-B*1502 Allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48(5):1015-8.
37. Tang TF, Hou L, Chen M, et al. HLA Haplotypes.in Singapore: A Study of mothers and their cord blood units. Human Immunology 2007; 68,430-8.
38. Chang CC, Too CL, Murad S, Hussein S. Association of HLA-B*1502 with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in Malaysian population. Proceeding in 7th Asian-Oceanian Epilepsy Congress, Xiamen. 2008
39. Romphruk A, Phongaen K, Chotechai J, Puapairoj C, Leelayuwat C, Romphruk AV. HLA-B*15 subtypes in the population of north-eastern Thailand. European Journal of Immunogenetics 2003; 30(2):153-8(6).
40. Han M, Tan Y, Guo Y, Romphruk A, Leelayuwat C, Stastny P. Allele Level typing of HLA-B locus by multiplexed single nucleotide extension (MSNE) and a study of B15 in different ethnic groups. Human Immunology 2004; 65(9-10)Suppl 1:S25
41. Loplumlert, J; Locharemkul, C; Shotelersuk, V; Limotai, C. A genetic screening of Steven Johnson syndrome from carbamazepine and phenytoin among people with epilepsy in Thailand. Epilepsia 2007; 48(Suppl7):S127
42. Hoa BK, Hang NT, Kashiwase K, et al. HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue Antigens 2008; 71(2):127-34.
43. Shankarkumar U. HLA-A, -B and -Cw allele frequencies in a Maratha population from Mumbai, India India Mumbai Marathas. Human Immunology 2004; 65(9-10):954-6.
44. Shankarkumar U. HLA-A, -B and -Cw allele frequencies in a Pawra population from Khandesh, India. Human Immunology 2004; 65(9-10):952-3.
45. Shankarkumar U. HLA-A, -B and -Cw allele frequencies in a Nadar population from Tamil Nadu, India. Human Immunology 2004; 65(9-10):958
46. Shankarkumar U. HLA-A, -B and -Cw allele frequencies in a Bhil population from Western India. Human Immunology 2004; 65(9-10):960-1.
47. Shankarkumar U HLA-A, -B and -Cw allele frequencies in a Parsi population from Western India. Human Immunology 2004; 65(9-10):992-3.
48. Rajalingam R, Parham P, Mehra NK, et al. HLA-A, -B, -Cw, -DQAl, -DQB1 and -DRB1 Alleles and KIR Alleles in a Hindu Population from Punjab, India. Human Immunology 2004; 65(9-10):958-60.
49. Johnson J, Thompson J, Hammond L, et al. HLA-A, B, DR and DQ Gene and haplotype frequencies in Sri Lankan Indian Tamils.Available in URL:http://www.wtail.org.uk/pdfdocs/P142/hfe%20poster.pdf
50. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions antiepileptic drugs. Epilepsia 1998; 39 (Suppl 7):S8-S16.
51. Kerr BM, Thummel KE,Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-79.
52. Madden S, Maggs JL, Park BK. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 1996; 24:469-79.
53. Bellucci G, Berti G, Chiappe C, Lippi A, Marioni F. The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10,11-epoxide. J Med Chem 1987; 30:768-73.
54. Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 1996; 24:509-14.
55. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155:462-72.
56. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118:728-33.
57. Nassif A, Bensussan A, Boumsell L, et al.Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-15.
58. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100: 136-41.
59. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5:889-99.
60. Pichler WJ. Modes of presentation of chemical neoantigens to the immune system. Toxicology 2002; 181-182:49-54.
61. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. Journal of Allergy and Clinical Immunology 2006; 118:233-41.
62. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Research 2001; 47:155-74.
63. Chang CC. Human leukocyte antigens in toxic epidermal necrolysis and Steven Johnson syndrome in Malaysian population. Advanced Master of Dermatology Thesis, Universiti Kebangsaan Malaysia
64. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-32.